Listed

Pfizer Inc: Form 10-Q for the period ended Sep 27, 2020

Filed with the SEC on Nov 5, 2020 and accepted by EDGAR at Nov 5, 2020, 21:57 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-09-27. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2020-06-29 to 2020-09-27$12.13bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2020-01-01 to 2020-09-27$35.96bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2020-06-29 to 2020-09-27$2.53bnus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2020-01-01 to 2020-09-27$7.19bnus-gaap:CostOfGoodsAndServicesSold
Selling, general and administrative3 months2020-06-29 to 2020-09-27$3.02bnus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2020-01-01 to 2020-09-27$8.92bnus-gaap:SellingGeneralAndAdministrativeExpense
Interest expense3 months2020-06-29 to 2020-09-27$416.0mus-gaap:InterestExpense
Interest expense9 months2020-01-01 to 2020-09-27$1.18bnus-gaap:InterestExpense
Income tax3 months2020-06-29 to 2020-09-27−$26.0mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2020-01-01 to 2020-09-27$968.0mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2020-06-29 to 2020-09-27$2.19bnus-gaap:NetIncomeLoss
Net income9 months2020-01-01 to 2020-09-27$9.02bnus-gaap:NetIncomeLoss
Diluted EPS3 months2020-06-29 to 2020-09-27$0.39us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2020-01-01 to 2020-09-27$1.60us-gaap:EarningsPerShareDiluted
Basic EPS3 months2020-06-29 to 2020-09-27$0.39us-gaap:EarningsPerShareBasic
Basic EPS9 months2020-01-01 to 2020-09-27$1.62us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2020-06-29 to 2020-09-275,633,000,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2020-01-01 to 2020-09-275,622,000,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2020-01-01 to 2020-09-27$8.78bnus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2020-01-01 to 2020-09-27$1.47bnus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases9 months2020-01-01 to 2020-09-27$0us-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2020-09-27$1.59bnus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-09-27$47.74bnus-gaap:AssetsCurrent
Total assetsAt period end2020-09-27$178.98bnus-gaap:Assets
Current liabilitiesAt period end2020-09-27$34.15bnus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-09-27$113.49bnus-gaap:Liabilities
Long-term debtAt period end2020-09-27$49.78bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2020-09-27$2.15bnus-gaap:LongTermDebtCurrent
Short-term borrowingsAt period end2020-09-27$10.99bnus-gaap:CommercialPaper
Shareholders' equityAt period end2020-09-27$65.26bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000078003-20-000070. Last ingested by Listed: Nov 12, 2026, 18:08 ET. Listed shows no prices and gives no investment advice.